<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39073834</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>925</StartPage><EndPage>938</EndPage><MedlinePgn>925-938</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2024.2305</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn &amp; Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary end point was the change of Movement Disorder Society Unified Parkinson's Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, -5.10 to 7.03, P&#x2009;=&#x2009;.75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%]; P&#x2009;=&#x2009;.003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">FMT was safe but did not offer clinically meaningful improvements. Further studies-for example, through modified FMT approaches or bowel cleansing-are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT04854291.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheperjans</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levo</LastName><ForeName>Reeta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Berta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe4;&#xe4;peri</LastName><ForeName>Mitja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>L&#xe4;&#xe4;peri Statistical Consulting, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Pedro A B</ForeName><Initials>PAB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolander</LastName><ForeName>Olli-Pekka</ForeName><Initials>OP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Velma T E</ForeName><Initials>VTE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetkas</LastName><ForeName>Nora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toivio</LastName><ForeName>Lotta</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kainulainen</LastName><ForeName>Veera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedorova</LastName><ForeName>Tatyana D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine - Nuclear Medicine and Positron Emission Tomography, Aarhus University, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahtinen</LastName><ForeName>Perttu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, P&#xe4;ij&#xe4;t-H&#xe4;me Central Hospital, Lahti, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Rebekka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tampere University Hospital and University of Tampere, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaasinen</LastName><ForeName>Valtteri</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Neurosciences, University of Turku and Neurocenter, Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satokari</LastName><ForeName>Reetta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arkkila</LastName><ForeName>Perttu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04854291</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2024 Sep 1;81(9):911-913. doi: 10.1001/jamaneurol.2024.2293</RefSource><PMID Version="1">39073794</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="Y">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Scheperjans reported grants from the Emil Aaltonen Foundation, Konung Gustav V:s och Drottning Victorias Stiftelse, the Olvi Foundation, the Yrj&#xf6; Jahnsson Foundation, the Stockmann Foundation, the Sigrid Jus&#xe9;lius Foundation, the Research Council of Finland, and the Hospital District of Helsinki and Uusimaa during the conduct of the study as well as grants from Renishaw; personal fees from AbbVie, Axial Biotherapeutics, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Lundbeck, Nordic Infucare, Adamant Health, and Biogen; and nonfinancial support from MRM Health and Novartis outside the submitted work. In addition, Dr Scheperjans had a patent for FI127671 issued, a patent for US10139408 issued, a patent for US11499971 issued, a patent for EP3149205 issued, and a patent for EP3789501 issued; is listed as inventor on the invention disclosure of the Parkinson disease dysbiosis test; and is founder of NeuroBiome Ltd. Dr Aho reported a patent for FI127671 issued, a patent for US10139408 issued, a patent for US11499971 issued, a patent for EP3149205 issued, a patent for EP3789501 pending, and a patent for US20230221314 pending. Dr Vetkas reported grants from the Orion Research Foundation, the Maire Taponen Foundation, the P&#xe4;ivikki and Sakari Sohlberg Foundation, and the Mary and George Ehrnrooth Foundation during the conduct of the study. Dr Fedorova reported grants from the Danish Parkinson Association outside the submitted work. Dr Ortiz reported grants from Emil Aaltonen foundation during the conduct of the study. Dr Kaasinen reported grants from the Finnish Alcohol Research Foundation, the Turku University Foundation, the Finnish Cultural Foundation, Turku University Hospital (state research funding) and personal fees from AbbVie Finland, Nordic Infucare AB, Adamant Health, and Orion Pharma outside the submitted work. Dr Satokari reported grants from the Sigrid Juselius Foundation (payment to University of Helsinki), the Research Council of Finland (payment to University of Helsinki), and the P&#xe4;ivikki and Sakari Sohlberg Foundation (payment to University of Helsinki) and other from the Finnish National Agency for Education (research scholarship; payment to University of Helsinki) during the conduct of the study as well as other from the Paulo Foundation (research scholarship; personal grant) and grants from the European Health and Digital Executive Agency Research project Endotarget (payment to the University of Helsinki), the European Health and Digital Executive Agency Research project Long-COVID (payment to the University of Helsinki), and the Cancer Foundation (payment to the University of Helsinki) outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39073834</ArticleId><ArticleId IdType="pmc">PMC11287445</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2024.2305</ArticleId><ArticleId IdType="pii">2821254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease&#x2014;from basic research to the clinic. Nat Rev Neurol. 2022;18(8):476-495. doi:10.1038/s41582-022-00681-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-022-00681-2</ArticleId><ArticleId IdType="pubmed">35750883</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho M, Macleod AD, Maple-Gr&#xf8;dem J, et al. . Early constipation predicts faster dementia onset in Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2021;7(1):45. doi:10.1038/s41531-021-00191-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-021-00191-w</ArticleId><ArticleId IdType="pmc">PMC8154963</ArticleId><ArticleId IdType="pubmed">34039994</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite Silva ABR, Gon&#xe7;alves de Oliveira RW, Di&#xf3;genes GP, et al. . Premotor, nonmotor and motor symptoms of Parkinson&#x2019;s disease: a new clinical state of the art. Ageing Res Rev. 2023;84:101834. doi:10.1016/j.arr.2022.101834</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2022.101834</ArticleId><ArticleId IdType="pubmed">36581178</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F, Aho V, Pereira PA, et al. . Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov Disord. 2015;30(3):350-358. doi:10.1002/mds.26069</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26069</ArticleId><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Aho VTE, Pereira PAB, Voutilainen S, et al. . Gut microbiota in Parkinson&#x2019;s disease: Temporal stability and relations to disease progression. EBioMedicine. 2019;44:691-707. doi:10.1016/j.ebiom.2019.05.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.05.064</ArticleId><ArticleId IdType="pmc">PMC6606744</ArticleId><ArticleId IdType="pubmed">31221587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilia R, Piatti M, Cereda E, et al. . Does gut microbiota influence the course of Parkinson&#x2019;s disease? a 3-year prospective exploratory study in de novo patients. J Parkinsons Dis. 2021;11(1):159-170. doi:10.3233/JPD-202297</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202297</ArticleId><ArticleId IdType="pubmed">33337387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiwaki H, Ito M, Hamaguchi T, et al. . Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2022;8(1):65. doi:10.1038/s41531-022-00328-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-022-00328-5</ArticleId><ArticleId IdType="pmc">PMC9160257</ArticleId><ArticleId IdType="pubmed">35650236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleine Bardenhorst S, Cereda E, Severgnini M, et al. . Gut microbiota dysbiosis in Parkinson disease: a systematic review and pooled analysis. Eur J Neurol. 2023;30(11):3581-3594. doi:10.1111/ene.15671</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15671</ArticleId><ArticleId IdType="pubmed">36593694</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh TS, Chong CW, Lim SY, et al. . Gut microbiome in Parkinson&#x2019;s disease: new insights from meta-analysis. Parkinsonism Relat Disord. 2022;94:1-9. doi:10.1016/j.parkreldis.2021.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2021.11.017</ArticleId><ArticleId IdType="pubmed">34844021</ArticleId></ArticleIdList></Reference><Reference><Citation>Boertien JM, et al. . Fecal microbiome alterations in treatment-naive de novo Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2022;8(1):129. doi:10.1038/s41531-022-00395-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-022-00395-8</ArticleId><ArticleId IdType="pmc">PMC9551094</ArticleId><ArticleId IdType="pubmed">36216843</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson JT, Holsinger RMD. The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review. Int J Mol Sci. 2023;24(2):24. doi:10.3390/ijms24021001</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24021001</ArticleId><ArticleId IdType="pmc">PMC9864694</ArticleId><ArticleId IdType="pubmed">36674517</ArticleId></ArticleIdList></Reference><Reference><Citation>Aho VTE, Houser MC, Pereira PAB, et al. . Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson&#x2019;s disease. Mol Neurodegener. 2021;16(1):6. doi:10.1186/s13024-021-00427-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00427-6</ArticleId><ArticleId IdType="pmc">PMC7869249</ArticleId><ArticleId IdType="pubmed">33557896</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie A, Ensink E, Li P, et al. . Bacterial butyrate in Parkinson&#x2019;s disease is linked to epigenetic changes and depressive symptoms. Mov Disord. 2022;37(8):1644-1653. doi:10.1002/mds.29128</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.29128</ArticleId><ArticleId IdType="pmc">PMC9545646</ArticleId><ArticleId IdType="pubmed">35723531</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzaei H, et al. . Probiotics and the treatment of Parkinson&#x2019;s disease: an update. Cell Mol Neurobiol. 2022;42(8):2449-2457. doi:10.1007/s10571-021-01128-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-021-01128-w</ArticleId><ArticleId IdType="pmc">PMC8770674</ArticleId><ArticleId IdType="pubmed">34283340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch B, Hartikainen A, Ronkainen A, Scheperjans F, Arkkila P, Satokari R. Development of a protocol for anaerobic preparation and banking of fecal microbiota transplantation material: evaluation of bacterial richness in the cultivated fraction. Microorganisms. 2023;11(12):11. doi:10.3390/microorganisms11122901</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11122901</ArticleId><ArticleId IdType="pmc">PMC10745795</ArticleId><ArticleId IdType="pubmed">38138045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammarota G, Ianiro G, Tilg H, et al. ; European FMT Working Group . European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-580. doi:10.1136/gutjnl-2016-313017</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313017</ArticleId><ArticleId IdType="pmc">PMC5529972</ArticleId><ArticleId IdType="pubmed">28087657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 Pt 2):620-625. doi:10.1016/j.gie.2008.05.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2008.05.057</ArticleId><ArticleId IdType="pmc">PMC2763922</ArticleId><ArticleId IdType="pubmed">19136102</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Tilley BC, Shaftman SR, et al. ; Movement Disorder Society UPDRS Revision Task Force . Movement Disorder Society&#x2013;sponsored revision of the Unified Parkinson&#x2019;s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170. doi:10.1002/mds.22340</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22340</ArticleId><ArticleId IdType="pubmed">19025984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. doi:10.1046/j.1365-2036.1997.142318000.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Karhu E, Forsg&#xe5;rd RA, Alanko L, et al. . Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners. Eur J Appl Physiol. 2017;117(12):2519-2526. doi:10.1007/s00421-017-3739-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00421-017-3739-1</ArticleId><ArticleId IdType="pmc">PMC5694518</ArticleId><ArticleId IdType="pubmed">29032392</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med. 2009;28(20):2509-2530. doi:10.1002/sim.3639</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3639</ArticleId><ArticleId IdType="pubmed">19610129</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson LM, Boulund F, Nilsson S, et al. . Dynamics of the normal gut microbiota: a longitudinal one-year population study in Sweden. Cell Host Microbe. 2022;30(5):726-739.e3. doi:10.1016/j.chom.2022.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.03.002</ArticleId><ArticleId IdType="pubmed">35349787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun MF, Zhu YL, Zhou ZL, et al. . Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson&#x2019;s disease mice: gut microbiota, glial reaction and TLR4/TNF-&#x3b1; signaling pathway. Brain Behav Immun. 2018;70:48-60. doi:10.1016/j.bbi.2018.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.02.005</ArticleId><ArticleId IdType="pubmed">29471030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Wang T, Chen X, Zhao Z, Chen Z. Gut microbiota relieves inflammation in the substantia nigra of chronic Parkinson&#x2019;s disease by protecting the function of dopamine neurons. Exp Ther Med. 2022;23(1):52. doi:10.3892/etm.2021.10974</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10974</ArticleId><ArticleId IdType="pmc">PMC8652398</ArticleId><ArticleId IdType="pubmed">34934429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Ning J, Bao XQ, et al. . Fecal microbiota transplantation protects rotenone-induced Parkinson&#x2019;s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021;9(1):226. doi:10.1186/s40168-021-01107-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01107-9</ArticleId><ArticleId IdType="pmc">PMC8597301</ArticleId><ArticleId IdType="pubmed">34784980</ArticleId></ArticleIdList></Reference><Reference><Citation>Borody T, Torres M, Campbell J, Hills L, Ketheeswaran S. Treatment of severe constipation improves Parkinson&#x2019;s disease (PD) symptoms. Am J Gastroenterol. 2009;104:S367. doi:10.14309/00000434-200910003-00999</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/00000434-200910003-00999</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Xu H, Luo Q, et al. . Fecal microbiota transplantation to treat Parkinson&#x2019;s disease with constipation: a case report. Medicine (Baltimore). 2019;98(26):e16163. doi:10.1097/MD.0000000000016163</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016163</ArticleId><ArticleId IdType="pmc">PMC6616439</ArticleId><ArticleId IdType="pubmed">31261545</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue LJ, Yang XZ, Tong Q, et al. . Fecal microbiota transplantation therapy for Parkinson&#x2019;s disease: a preliminary study. Medicine (Baltimore). 2020;99(35):e22035. doi:10.1097/MD.0000000000022035</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000022035</ArticleId><ArticleId IdType="pmc">PMC7458210</ArticleId><ArticleId IdType="pubmed">32871960</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal A, Zlotnik Y, Moyal-Atias K, Abuhasira R, Ifergane G. Fecal microbiota transplant as a potential treatment for Parkinson&#x2019;s disease&#x2014;a case series. Clin Neurol Neurosurg. 2021;207:106791. doi:10.1016/j.clineuro.2021.106791</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2021.106791</ArticleId><ArticleId IdType="pubmed">34237681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuai XY, Yao XH, Xu LJ, et al. . Evaluation of fecal microbiota transplantation in Parkinson&#x2019;s disease patients with constipation. Microb Cell Fact. 2021;20(1):10679198. doi:10.1186/s12934-021-01589-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12934-021-01589-0</ArticleId><ArticleId IdType="pmc">PMC8120701</ArticleId><ArticleId IdType="pubmed">33985520</ArticleId></ArticleIdList></Reference><Reference><Citation>DuPont HL, Suescun J, Jiang ZD, et al. . Fecal microbiota transplantation in Parkinson&#x2019;s disease&#x2014;a randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023;14:1104759. doi:10.3389/fneur.2023.1104759</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2023.1104759</ArticleId><ArticleId IdType="pmc">PMC10019775</ArticleId><ArticleId IdType="pubmed">36937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernova VO, Terveer EM, van Prehn J, et al. . Fecal microbiota transplantation for Parkinson&#x2019;s disease using levodopa&#x2014;carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube. Parkinsonism Relat Disord. 2023;111:105410. doi:10.1016/j.parkreldis.2023.105410</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2023.105410</ArticleId><ArticleId IdType="pubmed">37150070</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Tan G, Zhu Q, et al. . Efficacy of fecal microbiota transplantation in patients with Parkinson&#x2019;s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. 2023;15(2):2284247. doi:10.1080/19490976.2023.2284247</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2023.2284247</ArticleId><ArticleId IdType="pmc">PMC10841011</ArticleId><ArticleId IdType="pubmed">38057970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggeman A, Vandendriessche C, Hamerlinck H, et al. . Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson&#x2019;s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. 2024;71:102563. doi:10.1016/j.eclinm.2024.102563</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102563</ArticleId><ArticleId IdType="pmc">PMC11056595</ArticleId><ArticleId IdType="pubmed">38686220</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerstadt P, Aroniadis OC, Svedlund FL, et al. . Heterogeneity of randomized controlled trials of fecal microbiota transplantation in recurrent clostridioides difficile infection. Dig Dis Sci. 2022;67(7):2763-2770. doi:10.1007/s10620-021-07141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-021-07141-9</ArticleId><ArticleId IdType="pmc">PMC9236970</ArticleId><ArticleId IdType="pubmed">34275058</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu C, Yu L, Li Y, et al. . Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson&#x2019;s disease. Food Funct. 2023;14(8):3406-3422. doi:10.1039/D2FO03825K</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2FO03825K</ArticleId><ArticleId IdType="pubmed">36974511</ArticleId></ArticleIdList></Reference><Reference><Citation>Horv&#xe1;th K, Aschermann Z, Kov&#xe1;cs M, et al. . Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society&#x2013;sponsored Unified Parkinson&#x2019;s Disease Rating Scale. Mov Disord. 2017;32(5):789-793. doi:10.1002/mds.26960</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26960</ArticleId><ArticleId IdType="pubmed">28218413</ArticleId></ArticleIdList></Reference><Reference><Citation>Horv&#xe1;th K, Aschermann Z, &#xc1;cs P, et al. . Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015;21(12):1421-1426. doi:10.1016/j.parkreldis.2015.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.10.006</ArticleId><ArticleId IdType="pubmed">26578041</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E, Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord. 2011;17(8):587-592. doi:10.1016/j.parkreldis.2011.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2011.03.014</ArticleId><ArticleId IdType="pubmed">21530356</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r SI, Christensen AH, Lo BZS, et al. . Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115. doi:10.1136/gutjnl-2018-316434</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId><ArticleId IdType="pubmed">29980607</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios N, Hannoun A, Flahive J, et al. . Effect of levodopa initiation on the gut microbiota in Parkinson&#x2019;s disease. Front Neurol. 2021;12:574529. doi:10.3389/fneur.2021.574529</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.574529</ArticleId><ArticleId IdType="pmc">PMC7970035</ArticleId><ArticleId IdType="pubmed">33746867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Tohya M, Fukuda S, et al. . Effects of bowel preparation on the human gut microbiome and metabolome. Sci Rep. 2019;9(1):4042. doi:10.1038/s41598-019-40182-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40182-9</ArticleId><ArticleId IdType="pmc">PMC6411954</ArticleId><ArticleId IdType="pubmed">30858400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka J, Salonen A, Saloj&#xe4;rvi J, et al. . Effects of bowel cleansing on the intestinal microbiota. Gut. 2015;64(10):1562-1568. doi:10.1136/gutjnl-2014-307240</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307240</ArticleId><ArticleId IdType="pubmed">25527456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegelmaier T, Lebbing M, Duscha A, et al. . Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson&#x2019;s disease. Cells. 2020;9(2):9. doi:10.3390/cells9020376</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020376</ArticleId><ArticleId IdType="pmc">PMC7072275</ArticleId><ArticleId IdType="pubmed">32041265</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo JF, Alonso-Juarez M, Fekete R. intestinal decontamination therapy for dyskinesia and motor fluctuations in Parkinson&#x2019;s disease. Front Neurol. 2021;12:729961. doi:10.3389/fneur.2021.729961</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.729961</ArticleId><ArticleId IdType="pmc">PMC8461169</ArticleId><ArticleId IdType="pubmed">34566874</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudsen K, Fedorova TD, Bekker AC, et al. . Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson&#x2019;s disease: a colon transit and volume study. J Parkinsons Dis. 2017;7(2):359-367. doi:10.3233/JPD-161050</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-161050</ArticleId><ArticleId IdType="pubmed">28157109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>